Das Wirtschaftsportal ANIMAL PHARM veröffentlichte im Dezember 2016 einen Bericht über die Veterinärsparte des Mutterkonzerns der BREMER PHARMA GMBH. Den Bericht in englischer Sprache finden Sie hier:
Zydus Animal Health has been looking at various growth opportunities – both organic and inorganic – in its quest to become a global veterinary medicines provider, the firm told Animal Pharm.
Already one of the leaders in the Indian animal health industry, Zydus is currently integrating assets it acquired from Zoetis earlier this year.
Previously, the group strengthened its animal health business with the purchase of Germany's Bremer Pharma in 2011. The acquisition of Bremer established Zydus as an international player, while the Zoetis deal has consolidated the firm's domestic presence.
Dr Arun Atrey, who heads the animal health business of the group, said its parent company Cadila Healthcare has always been bullish on expansion opportunities as a part of the firm's growth strategy. He also said R&D and innovation will play a large role in the company's future.
"In India, we have one of the best formulation development facilities and innovation is our core strength with more than 1,200 research scientists spearheading innovation across the Zydus group," noted Dr Atrey.
"We have the distinction of launching the highest number of 'first-to-the-market' animal health products in India in the last 25 years because of our intrinsic strengths. As we aim to become the largest animal health company in India, new launches will be one of our major growth drivers."
Zydus Animal Health was formed after the group acquired the remaining 50% stake in its joint venture company Sarabhai Zydus Animal Health in 2007. The firm's product portfolio includes therapeutics for livestock and companion animals, as well as a range of poultry vaccines.
Published by Animal Pharm December 2016.